NASDAQ : KZIA
Kazia Therapeutics Limited — Key statistics
Healthcare · Biotechnology · Australia
Last price 8.5 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 116.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 109.90M |
| Enterprise Value | 63.64M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 13.70M |
| Shares Change (YoY) | +213.01% |
| Shares Change (QoQ) | +132.62% |
| Owned by Insiders (%) | 17.15% |
| Owned by Institutions (%) | 35.72% |
| Float | 11.35M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.78 |
| Forward PS | 151.71 |
| PB Ratio | 2.93 |
| P/TBV Ratio | 3.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 50.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.87 |
| Quick Ratio | 2.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -106.90% |
| Return on Assets (ROA) | -25.70% |
| Return on Invested Capital (ROIC) | -53.34% |
| Return on Capital Employed (ROCE) | -39.17% |
| Weighted Average Cost of Capital (WACC) | 16.73% |
| Revenue Per Employee | $211,072 |
| Profits Per Employee | -$2.53M |
| Employee Count | 6 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.07M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.27 |
| 52-Week Price Change | +2.69% |
| 50-Day Moving Average | 10.12 |
| 200-Day Moving Average | 10.55 |
| Relative Strength Index (RSI) | 41.40 |
| Average Volume (20 Days) | 221,091 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.31M |
| Short Previous Month | 1.17M |
| Short % of Shares Out | 8.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.27M |
| Gross Profit | 1.27M |
| Operating Income | -12.21M |
| Pretax Income | -16.28M |
| Net Income | -15.21M |
| EBITDA | -11.90M |
| EBIT | -12.21M |
| Loss Per Share | -$6.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 46.33M |
| Total Debt | 65,906 |
| Net Cash | 46.27M |
| Net Cash Per Share | $3.38 |
| Equity (Book Value) | 30.99M |
| Book Value Per Share | 2.73 |
| Working Capital | 30.42M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.08M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 326,307 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.08M |
| FCF Per Share | -$0.74 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -964.22% |
| Pretax Margin | -1,285.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -213.01% |
| Shareholder Yield | -213.01% |
| Earnings Yield | -85.03% |
| FCF Yield | -9.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $29.33 |
| Price Target Difference | 265.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -37.54% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.53 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |